RTW-backed Prolium emerges with $50M a year after China licensing deal: Finance Report

Closely following at least two recent deals involving T cell engagers for autoimmune disorders, Prolium — a start-up using the NewCo model — made its official debut with $50 million to drive development of a TCE for multiple immunology indications.

RTW Investments founded and invested in the series A of Prolium Bioscience Inc., which has been in stealth mode for at least a year. In January 2025, China-based Innocare Pharma Ltd. (HKEX:9969; Shanghai:688428) and Keymed Biosciences Inc. (HKEX:2162) disclosed Prolium’s existence by way of announcing a licensing deal...